Differences in the Unified Dyskinesia Rating Scale based on age, Parkinson´s Disease and Dyskinesias duration
Objective: To analyze the Unified Dyskinesia Rating Scale (UDysRS) scores on Historical, Objective parts and their differences based on age, Parkinson´s disease (PD) and dyskinesias…Clinical practice of levodopa in parkinsonism
Objective: This study is for the clinical effect of levodopa in parkinsonism. Background: Levodopa was common used in Parkinson disease. Levodopa induced dyskinesia(LID) is the…Levodopa induced dyskinesia is preventable (15 years experience using continuous dopaminergic stimulation)
Objective: To evaluate whether levodopa induced dyskinesia is preventable in the treatment of patients with Parkinson’s disease. Background: Dyskinesia is one of the major complications…Retrospective study on a cohort of 285 PD patients: Does the side of onset influence the global clinical phenotype?
Objective: To describe demographic and clinical characteristics of a cohort of 285 consecutive PD patients and to understand the phenotypic differences of right onset (RPD)…Lycopene ameliorates haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation
Objective: The study was undertakento investigate the role of striatal neurotransmitters and neuroinflammatory cytokines in the neuroprotective effect of lycopene against haloperidol induced orofacial dyskinesia…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…The BlueSky Project: monitoring motor and non-motor characteristics of people with Parkinson’s disease in the laboratory, a simulated apartment, and home and community settings
Objective: We present data collected for the BlueSky Project which aims to develop novel assessments of motor and non-motor function using mobile and wearable technology.…Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…Quantifying the Reproducibility of an In Vivo Assay: Examination of Historical Amantadine Effects in the macaque Model of L-DOPA-Induced Dyskinesia
Objective: This study was designed to assess the reproducibility of the amantadine anti-dyskinetic effect in the MPTP L-DOPA-Induced Dyskinesia (LID) macaque model for soundly defining…Objective Data in Parkinson’s Disease: A description of over 20,000 Parkinson’s symptom scores across the world using the Personal KinetiGraph (PKG)
Objective: The objective of this population study was to update & expand upon previous research [8] done to describe the objective symptom scores from a…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 49
- Next Page »